New York is currently home to 4599 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of refractory corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet-A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke Riboflavin 0.25% Transepithelial Solution) administered in conjunction with the UV-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: SightMD, Babylon, New York
Conditions: Keratitis, Corneal Ulcer
Single Versus Double Suture Cervical Cerclage to Prevent Preterm Birth
Recruiting
Cerclage placement is known to be beneficial in prevention of preterm birth when placed inn a certain subset of patients. Clinically, the number of sutures can also vary by surgeon preference to one or two sutures in one procedure. This is often decided in the operating room (OR) on the day of surgery but is poorly studied in the efficacy of maintaining the closed cervical length. Retrospective data found no significant benefit on placing two stitches instead of one in preterm birth rate but was... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: Stony Brook University, Stony Brook, New York
Conditions: The Primary Outcome is Preterm Delivery Before 28 Weeks Gestational Age Compared to Women With One vs Two Cerclages Placed
Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease
Recruiting
This is an imaging study designed to illuminate the function of the cholinergic system and its association with cognitive skills in people with Parkinson's disease. The hypothesis of this study is that there will be an association between cholinergic terminal density, sex hormones, and cognitive functioning. Participants will receive a PET and MRI scan along with a battery of neurocognitive tests at baseline and again at 18 months follow-up. Hormone levels will be measured at baseline.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/24/2022
Locations: Stony Brook Medical Center, Stony Brook, New York
Conditions: Parkinson's Disease
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
Recruiting
The purpose of this study is to study the long term safety and effectiveness of an artificial iris prosthesis for the treatment of iris defects.
Gender:
All
Ages:
3 years and above
Trial Updated:
10/21/2022
Locations: The Mackool Eye Institute, Astoria, New York
Conditions: Full Aniridia, Partial Aniridia
CERENOVUS Neurothrombectomy Devices Registry
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: Jacobs Institute/UB Neurosurgery, Inc., Buffalo, New York
Conditions: Cerebral Stroke
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: New York Medical College, Valhalla, New York
Conditions: Leukemia, Myeloid, Acute
High Intensity Interval Gait Training in Multiple Sclerosis
Recruiting
Over 90% of persons with MS (pwMS) complain of difficulty with walking. High intensity interval gait training (HIIGT), where persons alternate brief periods of walking at high speeds with periods of rest has been found to improve walking in other neurologic diagnoses. However its impact on pwMS is not known. Most gait training in MS is done continuously at a slower pace. The purpose of this study is to compare the effects of HIIGT to traditional Moderate Intensity Continuous Gait Training (MICGT... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: Hunter College, New York, New York
Conditions: Multiple Sclerosis
SP TLF Versus Ho:YAG Laser
Recruiting
The investigators aim to compare the performance of the Super Pulse Thulium fiber laser (SP TFL) with that of the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser. The investigators hypothesize that the electronically-modulated laser diodes, of the TFL offers the most comprehensive and flexible range of laser parameters among laser lithotripters leading to more efficient (4 times more) and effective stone dusting resulting in production of finer dust particles obviating the need for pos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Urinary Calculi
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Recruiting
The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To document the effects of lanreotide on markers of biochemical activity in participants with advanced or metastatic paraganglioma/ pheochromocytoma. Primary endpoints: • Assess efficacy by estimating the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Paraganglioma, Pheochromocytoma
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Recruiting
Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival. In an exploratory manner examine the extent of activation of the VEGFR pathway in pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and examine the relationship with response to therapy. Perform pharmacogenomics analyses of drug metabolism and tran... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Pheochromocytoma, Paraganglioma
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
Recruiting
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/03/2022
Locations: NYU Lagone Health, New York, New York
Conditions: Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial
Recruiting
This is a multi-center, randomized, double-masked clinical trial. All study devices are market approved/cleared in the localities where the study is conducted. Subjects will be randomly assigned to wear NaturalVue Sphere single vision contact lenses (SVCL) or NaturalVue Multifocal (NVMF) soft contact lenses for a total of three years.
Gender:
All
Ages:
Between 7 years and 13 years
Trial Updated:
10/03/2022
Locations: Cooper Eye Care, New York, New York
Conditions: Myopia